Rosiglitazone inhibits vascular K(ATP) channels and coronary vasodilation produced by isoprenaline

BACKGROUND AND PURPOSE: Rosiglitazone is an anti-diabetic drug improving insulin sensitivity and glucose uptake in skeletal muscle and adipose tissues. However, several recent clinical trials suggest that rosiglitazone can increase the risk of cardiovascular ischaemia, although other studies failed...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Yu, Lei, Jin, Xin, Yang, Yang, Cui, Ningren, Jiang, Chun
Materialtyp: Artigo
Språk:Inglês
Publicerad: Blackwell Publishing Ltd 2011
Ämnen:
Research Papers
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3246668/
https://ncbi.nlm.nih.gov/pubmed/21671900
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1476-5381.2011.01539.x
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk